November 4, 2025 — Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in investor conferences in November and December.
**November 4, 2025 —** Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company, announced that management will participate in the Jefferies London Global Healthcare Conference on Tuesday, November 18, 2025, at 1:00 p.m. GMT / 8:00 a.m. ET, and the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025, at 8:20 a.m. ET.
Live webcasts of each event will be accessible on the “Investors” page of Enanta’s website at www.enanta.com. Replays will be archived for at least 30 days.
Enanta is focused on discovering and developing small molecule drugs for virology and immunology. Its clinical programs target respiratory syncytial virus (RSV), and its immunology pipeline aims to develop treatments for inflammatory diseases.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of a leading treatment for hepatitis C virus (HCV) infection, sold by AbbVie as MAVYRET® (U.S.) and MAVIRET® (ex-U.S.). Royalties from these HCV products fund Enanta’s operations.
Source: Enanta Pharmaceuticals, Inc.
